No Data
No Data
Zhito Hong Kong Stock Investment Journal | November 21
Hong Kong Stock Investment Log | November 21, 2024
Insigma Technology (600797.SH): Jointly invested company Jiuyuan Genes plans to list on the main board of the Hong Kong Stock Exchange.
On November 20, Gelonhui reported that insigma technology (600797.SH) announced that its wholly-owned subsidiary, Zhejiang Insigma Technology Venture Capital Co., Ltd. (referred to as "Insigma Venture Capital"),'s participating company Hangzhou Jiuyuan Gene Engineering Co., Ltd. (referred to as "Jiuyuan Gene") disclosed its prospectus on the Hong Kong Stock Exchange website on November 20, 2024, planning a global offering. Among them, the Hong Kong public offering consists of 4,540,000 H shares (subject to reallocation), and the international offering consists of 40,858,800 H shares (subject to reallocation and may be adjusted based on the exercise of the over-allotment option), with an offer price.
Hangzhou Jiuyuan Gene Engineering Launches Up to HK$570 Million Hong Kong IPO
Jiuyuan Genomics (02566.HK) is expected to be listed on November 28, with multiple cornerstone investors including fosun pharma.
Genomics Nine Limited (02566.HK) has announced that the company plans to globally offer 45.3988 million H shares, with 4.54 million shares to be offered in Hong Kong, and 40.8588 million shares to be offered internationally; the IPO will take place from November 20 to November 25, 2024, with the expected pricing date being November 26; the offer price will be between HK$11.48 and HK$12.56 per share, with a trading unit of 200 shares per board lot; Huatai International is the sole sponsor; the anticipated shares will commence trading on the Stock Exchange of Hong Kong on November 28, 2024.
No Data
No Data